Table 2.
Survival analysis of all single markers for overall survival and breast cancer-specific survival in all patients and in those who received chemotherapy.
| n | Overall survival | Breast cancer specific survival | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95%CI | p value | ||
| All patients | |||||||
| CD3+ (high vs. low) | 121 vs. 120 | 0.84 | 0.53–1.35 | 0.479 | 0.96 | 0.54–1.71 | 0.881 |
| CD8+ (high vs. low) | 122 vs. 121 | 0.81 | 0.50–1.31 | 0.386 | 1.08 | 0.61–1.92 | 0.785 |
| CD20+ (high vs. low) | 121 vs. 118 | 0.96 | 0.60–1.54 | 0.852 | 1.12 | 0.63–2.00 | 0.708 |
| CD68+ (high vs. low) | 122 vs. 121 | 0.99 | 0.61–1.60 | 0.968 | 0.82 | 0.46–1.47 | 0.507 |
| PD-1+ (high vs. low) | 120 vs. 119 | 0.80 | 0.50–1.29 | 0.359 | 0.87 | 0.48–1.56 | 0.632 |
| PD-L1+ (high vs. low) | 122 vs. 121 | 0.60 | 0.36–0.96 | 0.034 | 0.60 | 0.33–1.09 | 0.093 |
| FOXP3+ (high vs. low) | 105 vs. 98 | 0.68 | 0.39–1.20 | 0.182 | 1.09 | 0.55–2.19 | 0.800 |
| Patients who received chemotherapy | |||||||
| CD3+ (high vs. low) | 95 vs. 78 | 0.64 | 0.35–1.18 | 0.150 | 0.64 | 0.32–1.27 | 0.204 |
| CD8+ (high vs. low) | 97 vs. 77 | 0.61 | 0.33–1.13 | 0.115 | 0.70 | 0.35–1.39 | 0.312 |
| CD20+ (high vs. low) | 91 vs. 80 | 1.61 | 0.84–3.07 | 0.152 | 1.50 | 0.74–3.06 | 0.261 |
| CD68+ (high vs. low) | 87 vs. 87 | 0.90 | 0.48–1.69 | 0.741 | 0.80 | 0.40–1.59 | 0.522 |
| PD-1+ (high vs. low) | 88 vs. 83 | 0.63 | 0.34–1.18 | 0.152 | 0.72 | 0.36–1.44 | 0.346 |
| PD-L1+ (high vs. low) | 95 vs. 79 | 0.47 | 0.25–0.89 | 0.020 | 0.46 | 0.23–0.94 | 0.033 |
| FOXP3+ (high vs. low) | 78 vs. 67 | 0.58 | 0.26–1.26 | 0.170 | 0.81 | 0.34–1.97 | 0.645 |